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background: One third of the elderly population with symp-
tomatic calcified aortic stenosis cannot undergo surgery due 
to their high operative risk. The transcatheter aortic-valve 
implantation (TAVI) has emerged as an alternative therapy 
for this group of patients. Methods: All patients submitted 
to TAVI from November 2008 to April 2012 were included 
in our study. We report the baseline clinical characteristics, 
procedural data, hospital outcomes and clinical follow-up 
of this population. Definitions were based on the Valve 
Academic Research Consortium criteria. Results: TAVI was 
performed in 23 patients, with 79 ± 6.7 years of age, and 
56% were female. The EuroSCORE was 20.4 ± 11.1%. The 
CoreValve® prosthesis was used in 19 patients (82.6%) and 
the Edwards SAPIEN™ valve was used in the remaining ones. 
Procedure success rate was 96%. The mean follow-up was 
22 ± 12.8 months, with 6 deaths (26.1%) in this period, 
3 of which were observed in the first 30 days (13%) and 
other 2 (21.7%) by the end of the first year. One patient 
had a transient ischemic attack during hospitalization 
(4.3%), but there were no episodes of stroke or myocardial 
infarction in the periprocedural period or in the follow-up. 
The composite safety endpoint at 30 days was observed 
in 5 patients (21.7%) and the composite efficacy endpoint 
at 12 months was 78.3%. Conclusions: The results of this 
study demonstrate that TAVI is an attractive procedure for 
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ResUMo
Resultados Imediatos e seguimento Clínico dos Pacientes 
submetidos a Implante Valvar Aórtico Transcateter
Introdução: Um terço da população idosa portadora de este-
nose aórtica calcificada sintomática não apresenta condições 
cirúrgicas em decorrência do elevado risco operatório. O 
implante valvar aórtico transcateter (IVAT) surgiu como uma 
alternativa terapêutica para esses pacientes. Métodos: Incluímos, 
no período de novembro de 2008 a abril de 2012, todos os 
pacientes submetidos a IVAT em nosso serviço. Relatamos as 
características clínicas basais, os dados dos procedimentos, os 
resultados hospitalares e o seguimento clínico dessa população. 
As definições utilizadas foram baseadas nos critérios do Valve 
Academic Research Consortium. Resultados: O IVAT foi reali-
zado em 23 pacientes, com 79 + 6,7 anos de idade, 56% do 
sexo feminino. O EuroSCORE foi de 20,4 + 11,1%. A prótese 
CoreValve® foi utilizada em 19 pacientes (82,6%) e a Edwards 
SAPIENTM nos demais. A taxa de sucesso do procedimento foi 
de 96%. O tempo médio de seguimento clínico foi de 22 + 
12,8 meses, observando-se 6 óbitos (26,1%) nesse período, 3 
dos quais ocorreram nos primeiros 30 dias (13%) e outros 2 
(21,7%), até o final do primeiro ano. Um paciente apresentou 
ataque isquêmico transitório na fase hospitalar (4,3%), mas não 
ocorreram episódios de acidente vascular encefálico ou de infarto 
do miocárdio no período periprocedimento ou no acompanha-
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mento tardio. O desfecho combinado de segurança aos 30 dias 
ocorreu em 5 pacientes (21,7%) e o desfecho combinado de 
eficácia aos 12 meses foi de 78,3%. Conclusões: Os resultados 
obtidos neste estudo demonstram o IVAT como procedimento 
atrativo para o tratamento de pacientes portadores de estenose 
aórtica calcificada de alto risco cirúrgico.
DesCRIToRes: Estenose da valva aórtica. Próteses valvulares 
cardíacas. Implante de prótese de valva cardíaca.
C alcified aortic stenosis is the most commonly diagnosed valve disease in the United States and Europe,1 and its severe form affects 2% of the 
population older than 65 years of age.2 Considering 
that this is the rate of prevalent severe aortic stenosis 
in the Brazilian population, 380,000 cases are expected 
to be diagnosed by 2020 and approximately 1,000,000 
cases by 2050.3 
Initially considered to be natural valve tissue de-
generation, current data supports the hypothesis that 
calcified aortic stenosis is caused by an inflammatory 
process, similar to atherosclerosis. The accumulation 
of oxidised lipoproteins is observed in the intima, as 
well as in endothelial activation and the recruitment 
of T lymphocytes and monocytes.4 Several mechanisms 
have been proposed for valve tissue calcification, and 
the transdifferentiation of myofibroblasts into osteoblasts 
is one of them.5
In adult patients with aortic stenosis, the obstruc-
tion to blood flow increases gradually over the years. 
During this period, there is a gradual adaptation of the 
left ventricle to pressure overload through the develop-
ment of concentric myocardial hypertrophy. This results 
in diastolic dysfunction, reduced coronary flow reserve, 
myocardial ischaemia, and eventually left ventricular 
systolic dysfunction.6
Typically, patients with aortic stenosis remain 
asymptomatic for a long period of time; however, 
after the onset of symptoms, the prognosis is poor, 
with an interval to death of two years for those with 
heart failure, three years for syncope, and five years 
for angina pectoris.7
The standard treatment for symptomatic patients 
is surgical replacement of the aortic valve.8 However, 
approximately one-third of the elderly population with 
this disease cannot benefit from treatment due to the 
presence of comorbidities or other conditions that are 
unfavourable to surgery.9,10 These patients have adverse 
outcomes, with a one to two year survival rate of 50%.11,12
Transcatheter aortic valve implantation (TAVI), 
introduced by Cribier et al.,13 has emerged as an 
attrac tive alternative treatment for these patients, and 
its use has rapidly increased. The initial results were 
favourable,14,15 and the use of TAVI in patients with 
contraindications to surgery was shown to be superior 
to medical therapy.12,16 As such, this technique has been 
adapted by several departments throughout the world, 
beginning with this department in 2008. This study aims 
to present the immediate and long-term outcomes in 
this group of patients, using the criteria proposed by 
the Valve Academic Research Consortium (VARC).17
Methods
Patients
In November of 2008, a multidisciplinary team 
consisting of specialists in anesthesia, cardiology, 
echocardiography, haemodynamics, interventional radiol-
ogy, and cardiac surgery at the Hospital Beneficência 
Portuguesa de São Paulo started the TAVI program. All 
patients at this hospital who underwent TAVI between 
November of 2008 and April of 2012 were included in 
this registry. This study was approved by the institution 
ethics and research committee under protocol number 
669-11/CAAE: 0104.1.360.000-11.
selection criteria
Individuals were selected based on clinical criteria 
and the morphological parameters of the aortic valve/
aorta and the access route to determine the technical 
feasibility of percutaneous valve replacement.18 For that 
purpose, transthoracic echocardiography with colour 
Doppler, multi-detector CT angiotomography, and an-
giography of the ascending aorta, iliac-femoral territory, 
and coronary arteries were performed.
Patients in this registry included those with an aortic 
valve area < 1 cm2 or with an indexed aortic valve area 
≤ 0.6 cm2/m2, symptomatic patients with an aortic valve 
annulus diameter ≥ 20 mm and ≤ 27 mm, an ascending 
aortic diameter ≤ 45 mm, and a logistic EuroSCORE 
≥ 15% or those at high surgical risk as established by a 
multidisciplinary assessment, and considering the following 
comorbidities: hepatic cirrhosis, pulmonary hypertension 
> 60 mmHg, extensively calcified aorta (porcelain aorta), 
recurrent pulmonary embolism, right ventricular failure, 
or refusal of the patient to undergo surgery.
Ghandour et al. 
Transcatheter Aortic-Valve Implantation
Rev Bras Cardiol Invasiva. 
2012;20(3):260-6
262
device and procedure description
One of two commercially available prostheses 
was used: the third generation CoreValve® prosthesis 
(Medtronic Inc. – Minneapolis, USA) or the Edwards 
SAPIENTM XT prosthesis (Edwards Lifesciences Inc. – 
Irvine, California, USA).
The CoreValve® prosthesis (Figure 1) consists of 
three porcine pericardium leaflets mounted on a Ni-
tinol self-expandable stent. The prosthesis diameters 
used were 26 mm, for a valve annulus of 20 mm to 
23 mm, and 29 mm, for a valve annulus > 23 mm to 
27 mm. The Edwards SAPIENTM XT prosthesis (Figure 
2) consists of three bovine pericardial leaflets mounted 
on a cobalt-chromium balloon-expandable stent. This 
device is available in Brazil with diameters of 23 mm, 
for an annulus of 21 mm to 23 mm, and of 26 mm, 
for a valve annulus > 23 to 24.5 mm. Both systems 
use 18 F diameter sheaths.
The procedures were performed under general anes-
thesia or sedation, depending on the patient’s clinical 
condition and the prosthesis chosen, because it is neces-
sary to use transoesophageal echocardiography to guide 
prosthetic implantations with the Edwards SAPIENTM 
XT. All patients received 200 mg of acetylsalicylic acid 
and 300 mg of clopidogrel orally 24 hours before the 
procedure and were maintained for six months post-
procedure with 100 mg of acetylsalicylic acid and 75 mg 
of clopidogrel daily. At the beginning of each procedure, 
unfractionated heparin was administered intravenously 
(100 IU/kg) with adequate corrections to achieve an 
activated clotting time between 300 and 350 seconds. 
The implantation techniques for these two pros-
theses have been previously described in detail.14,19 
Briefly, the retrograde access was used, preferably by 
puncture of the femoral artery. Following the selective 
catheterisation of the left ventricle, aortic valvuloplasty 
was performed with a balloon when using the Edwards 
SAPIENTM XT prosthesis or, when necessary, when using 
the CoreValve® prosthesis. During balloon pre-dilation, 
a temporary pacemaker was used to raise the heart rate 
to between 180 beats to 220 beats per minute, thus 
preventing balloon displacement at the time of inflation. 
The stent was then implanted. At the end of the proce-
dure, a control ascending aortography was performed 
to assess the presence of perivalvular regurgitation. 
Hemostasis was performed with the vascular occlusion 
device Perclose ProGlide (Abbott, Inc. – Abbott Park, 
USA). Patients were referred to the intensive care unit, 
where they remained for at least 48 hours. They also 
underwent preventive maintenance with a transvenous 
pacemaker during that period, as there was a possibility 
complete atrioventricular block.
Clinical follow-up was performed through medical 
consultation or by contacting patients by telephone.
study definitions and endpoints
Procedural success was defined as the implanta-
tion of a properly functioning single prosthesis in the 
correct position. 
The primary study endpoint was defined as the 
number of all-cause mortality at 30 days and at one 
year. The combined safety endpoint at 30 days was 
Figure 1 – Aortography showing the CoreValve® prosthesis in the aortic 
position without regurgitation.
Figure 2 – Aortography showing the Edwards SAPIENTM XT prosthesis 
in the aortic position without regurgitation.
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defined as the number of occurrences of death from 
any cause, major stroke, periprocedural myocardial 
infarctions, life-threatening bleeding, need for dialyses, 
or severe vascular complications within 30 days of the 
procedure. The combined efficacy endpoint at one year 
was defined as the number of survivals, free of death 
by any cause, treatment failure for aortic stenosis, or 
prosthesis dysfunction.
Other assessed outcomes were cardiovascular 
mortality at 30 days and one year, the incidence of 
stroke and acute myocardial infarction, the occurrence 
of major vascular complications, the need for implanta-
tion of a permanent pacemaker, and new left bundle 
of His branch block.
Results
From November of 2008 to April of 2012, 23 
patients were included in the registry, and their out-
comes were followed for a mean period of 22 ± 12.8 
months, ranging from three months to 44 months. The 
mean age was 79 ± 6.7 years, and 56% of the patients 
were female. All patients were white; 87% of individu-
als had hypertension, 65% had dyslipidemia, and 30% 
had diabetes mellitus.
The patients had an average aortic valve area of 0.53 
± 0.14 cm2, 35% had reported episodes of syncope, 30% 
had angina, and 96% had dyspnoea on exertion, with 
9% in functional class II, 74% in functional class III, and 
17% in functional class IV, as categorised according to 
the criteria set forth by the New York Heart Association 
(NYHA). The mean logistic EuroSCORE was 20.4 ± 11.1%. 
The main baseline characteristics are presented in Table 1.
The annulus diameter of the aorta was 22.4 ± 2.2 
mm and the ascending aorta was 35.3 ± 3.9 mm. The 
left ventricle ejection fraction was 66 ± 11%, with three 
patients showing left ventricular systolic dysfunction. 
The maximum peak gradient observed between the left 
ventricle and the aorta was 92.1 ± 23.2 mmHg and 
the mean was 54.1 ± 14.5 mmHg. Echocardiographic 
data are shown in Table 2.
Procedural data
Sedation was used in 12 procedures (52%), while 
the remainder of the procedures were performed under 
general anesthesia. A right femoral artery puncture was 
used in 15 (65%), while the other patients under went 
surgical dissection. The CoreValve® prosthesis was im-
planted in 19 cases and the Edwards SAPIENTM XT, in 
four. A pre-dilatation balloon catheter was used in seven 
(37%) patients receiving the CoreValve® prosthesis. Post-
dilatation was performed in seven (30%) procedures. 
The main procedural data are shown in Table 3.
Technical success of the implant was achieved in 
95.7% of cases. In one patient, the prosthesis failed 
TAbLe 1 
baseline clinical characteristics  
of patients undergoing transcatheter aortic  
valve implantation (TAVI)
Characteristics n = 23
Female gender, n (%) 13 (56)
Age, years 79 ± 6.7
Functional class NYHA, n (%)
 I 2 (9)
 III 16 (74)
 IV 4 (17)
Syncope, n (%) 8 (35)
Angina, n (%) 7 (30)
Systemic arterial hypertension, n (%) 20 (87)
Dyslipidaemia, n (%) 14 (61)
Diabetes mellitus, n (%) 8 (35)
Coronary artery disease*, n (%) 14 (70)
Previous acute myocardial  
infarction, n (%) 4 (17)
Previous coronary artery bypass 
grafting, n (%) 4 (17)
Previous percutaneous coronary 
intervention, n (%) 10 (43)
Creatinine clearance, mL/min 48 ± 17.12
Peripheral vascular disease, n (%) 5 (22)
Pulmonary hypertension†, n (%) 5 (22)
Chronic obstructive pulmonary 
disorder‡, n (%) 3 (13)
Mean logistic EuroSCORE, % 20.4 ± 11.1
* Stenosis > 50% on coronary angiography.
† Systolic pulmonary artery pressure > 60 mmHg.
‡ Chronic use of bronchodilators or steroids for pulmonary 
disease or Spirometry with forced expiratory volume in one 
second < 60% predicted or PaO2 < 60 mmHg in ambient air 
and PaCO2 > 50 mmHg in ambient air.
n = number of patients; NYHA = New York Heart Association.
to implant in the correct position, and progressed to 
moderate heart failure. This called for a repositioning of 
the prosthesis, which was successfully performed using 
a loop snare. The maximum gradient between the left 
ventricle and the aorta after valve implantation was 
17.9 ± 7.3 mmHg. The left ventricular ejection fraction 
achieved was 71% ± 6.6% after the procedure, with a 
percentage increase of 7.3% from before the procedure. 
Mild or absent aortic regurgitation was observed in 17 
(74%) patients.
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Pre-transcatheter aortic valve implantation 
echocardiographic characteristics 
Pre-implantation echocardiographic 
variables n = 23
Left ventricular ejection  
fraction, %
66 ± 11
Aortic valve area, cm² 0.53 ± 0.14
Peak systolic gradient, mmHg 92.1 ± 23.2
Mean systolic gradient, mmHg 54.1 ± 14.5
Aortic valve annulus, mm 22.4 ± 2.2
Ascending aorta, mm 35.3 ± 3.9
Aortic regurgitation, n (%)
 Absent/mild 21 (91.3)
 Moderate 2 (8.7)
 Severe 0
n = number of patients.
The combined efficacy endpoint at 12 months was 
78.3% (18/23), with the occurrence of two additional 
non-cardiovascular deaths between 30 days and one 
year. There were no admissions due to aortic stenosis 
treatment failure during this period and no malfunctions 
were detected in the implanted prosthesis.
TAbLe 3 
Characteristics related to the procedure  
and in-hospital clinical events
Variables n = 23
Access route, n (%)
Femoral puncture 15 (65)
Femoral dissection 8 (35)
Anaesthesia, n (%)
Sedation 12 (52)
General anaesthesia 11 (48)
Prosthesis used
CoreValve®, n (%)
26 mm 8 (35)
29 mm 11 (48)
Edwards SAPIEN™ XT
26 mm 3 (13)
29 mm 1 (4)
Pre-dilation CoreValve®, n (%) 7 (37)
Post-dilation CoreValve®, n (%)/
Edwards SAPIEN™ XT, n (%) 7 (30)
Post-implantation aortic  
regurgitation degree, n (%)
0 or I 20 (87)
II 2 (8.7)
III 1 (4.3)
Clinical events, n (%)
Cardiovascular death 3 (13)
Stroke/TIA 1 (4.3)
AMI 0
Definitive pacemaker 4 (17.4)
Vascular complication 2 (8.6)
Arterial thrombosis 1 (4.3)
Haematoma with blood  
transfusion 1 (4.3)
Combined 30-day endpoint of safety 5 (21.7)
TIA= transient ischaemic attack; AMI = acute myocardial 
infarction.
Clinical outcomes
The mean follow-up time for patients was 22 ± 
12.8 months. Six deaths, regardless of cause, were 
observed (26.1%) during this period, three of which 
occurred in the first 30 days (13%) and two of which 
(21.7%) occurred by the end of the first year. There 
were three cardiovascular deaths, all in the first month 
after the procedure, three non-cardiovascular deaths 
at four months due to pneumonia, and another two 
at 12 months and 33 months after the procedure due 
to gastrointestinal complications. 
The combined safety endpoint at 30 days was 
21.7% (5/23). There were three cardiovascular deaths, 
one arterial thrombosis and one bleeding event requiring 
transfusion. One patient (4.3%) had a transient ischaemic 
attack in the hospital, but there were no episodes of 
stroke or myocardial infarction in both the periproce-
dural period or during the clinical follow-up period. 
Among the study patients, four had pacemakers 
implanted before the procedure, four required definitive 
pacemaker implants in the hospital, and one patient had 
the device implanted three months after TAVI. Left bundle 
branch blockage before the procedure was observed 
in five patients, while nine patients (50%) presented 
new left bundle branch blockages. Electrocardiographic 
alterations after TAVI are described in Table 4.
The functional class of patients during evolution 
is shown in Figure 3.
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TAVI enables the approach of patients with surgical 
contraindications, such as high-risk patients or those 
with exclusionary features, such as a porcelain aorta. 
In the present sample, patients with high-risk profiles, 
those who were elderly (mean age of 79 years), and 
those with multiple risk factors for atherosclerosis and 
a EuroSCORE of 20.4 were selected.
TAVI was successful in 22 of the 23 patients. The 
individual defined as a failure presented moderate 
aortic regurgitation at the end of the procedure, but 
was resolved with prosthesis repositioning two days 
after the implantation.
A 13% overall mortality at 30 days is similar to 
previously published reports: Gilard et al.,20 9.7%; Lemos 
et al.,21 8.4%; Gurvitch et al.,22 9.4%; and Stähli et al.,23 
11.5%. The 21.7% safety outcome obtained in this series 
is comparable to that of Gurvitch et al.22 (18.4%) and 
TAbLe 4  
eCG abnormalities after transcatheter  
aortic valve implantation
electrocardiographic abnormalities  
after implantation
Complete left bundle blockage,  
n (%) 9/18 (50)
AVB First degree, n (%) 3/19 (15.8)*
AVB Second degree Mobitz type II, n (%) 1/19 (5.3)*
Total AVB, n (%) 4/19 (21.1)*
*All cases with CoreValve® implant.  
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Figure 3 – Functional class evolution of patients submitted to trans-
catheter aortic valve implantation. n = number of patients.
Stähli et al.23 (20.8%). This outcome evaluates events 
related to the technical complications of the procedure 
within 30 days. The 78.3% combined efficacy endpoint 
at one year was similar to the endpoint reported by 
Stähli et al.23 (70.2%). This outcome of effectiveness 
evaluates therapeutic failure-free survival, with the 
proper performance of the prosthesis.
TAVI provided marked clinical improvement, as 
shown in Figure 3. At baseline, 74% of patients were 
in functional class III and 17% were in functional class 
IV. Immediate after the operation and at their 30-day 
assessment, 94.7% and 91.3% of patients, respectively, 
were in functional class I or II, and remained at satis-
factory levels in late follow-up.
Procedural completion through the femoral puncture 
technique and hemostasis using the Perclose ProGlide 
system was feasible, with only one vascular complica-
tion in the present study. One patient required surgical 
treatment for femoral artery thrombosis.
The main adverse effect observed with this technique 
was the need to implant a pacemaker, which occurred 
in four patients (21.1%), all of whom had received the 
CoreValve™ prosthesis. In comparison, this complica-
tion can occur in up to 8% of those undergoing the 
conventional surgical procedure.24,25 Some series have 
shown rates of up to 30.4% for patients needing pace-
makers after TAVI.25
study limitations
The study was limited by its observational nature, 
its single-centre design, and its small sample size.
ConClusions
These results demonstrate that TAVI is an attractive 
alternative for the treatment of severe calcified aortic 
stenosis in high-risk surgical patients. A thorough evalu-
ation is crucial for procedural success and to reduce 
complications. However, the long-term effectiveness 
needs to be demonstrated, and technological develop-
ments may further improve outcomes and expand the 
indications for patients at lower risk.
ConfliCt of inteRest
The authors declare no conflicts of interest.
RefeRenCes
 1. Iung B, Baron G, Butchart EG, Delahaye F, Gohlke-Barwolf C, 
Levang OW, et al. A prospective survey of patients with valvular 
heart disease in Europe: the Euro Heart Survey on Valvular 
Heart Disease. Eur Heart J. 2003;24(13):1231-43.
 2. Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. 
Association of aortic-valve sclerosis with cardiovascular 
mortality and morbidity in the elderly. N Engl J Med. 
1999;341(3):142-7.
Ghandour et al. 
Transcatheter Aortic-Valve Implantation
Rev Bras Cardiol Invasiva. 
2012;20(3):260-6
266
 3. Oliveira JC, Albuquerque FRP, Lins IB; Instituto Brasileiro de 
Geografia e Estatística (IBGE). Projeção da população do 
Brasil por sexo e idade para o período 1980-2050 – revisão 
2004. Rio de Janeiro; 2004. Available from: <http://www. 
ibge.gov.br/home/estatistica/populacao/projecao_da_populacao/ 
metodologia.pdf>.
 4. Freeman RV, Otto CM. Spectrum of calcific aortic valve disease: 
pathogenesis, disease progression, and treatment strategies. 
Circulation. 2005;111(24):3316-26.
 5. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, 
Donovan J, Springett M, et al. Human aortic valve calcifica-
tion is associated with an osteoblast phenotype. Circulation. 
2003;107(17):2181-4.
 6. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009; 373 
(9667):956-66.
 7. Carabello BA, Green LH, Grossman W, Cohn LH, Koster JK, 
Collins JJ Jr. Hemodynamic determinants of prognosis of aortic 
valve replacement in critical aortic stenosis and advanced 
congestive heart failure. Circulation. 1980;62(1):42-8.
 8. Tarasoutchi F, Montera MW, Grinberg M, Barbosa MR, 
Piñeiro DJ, Sanches CRM, et al. Diretriz Brasileira de Valvopatias 
– SBC 2011. I Diretriz Interamericana de Valvopatias – SIAC 
2011. Arq Bras Cardiol. 2011;97(5 Supl. 1):1-67.
 9. Iung B, Cachier A, Baron G, Messika-Zeitoun D, Delahaye F, 
Tornos P, et al. Decision-making in elderly patients with severe 
aortic stenosis: why are so many denied surgery?. Eur Heart 
J. 2005;26(24):2714-20.
10. Bouma BJ, van Den Brink RB, van Der Meulen JH, Verheul HA, 
Cheriex EC, Hamer HP, et al. To operate or not on elderly 
patients with aortic stenosis: the decision and its consequences. 
Heart. 1999;82(2):143-8.
11. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile 
and natural history of 453 nonsurgically managed patients with 
severe aortic stenosis. Ann Thorac Surg. 2006;82(6):2111-5.
12. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, 
et al. Transcatheter aortic-valve implantation for aortic steno-
sis in patients who cannot undergo surgery. N Engl J Med. 
2010;363(17):1597-607.
13. Cribier A, Eltchaninoff H, Bash A, Borenstein N, Tron C, Bauer F, 
et al. Percutaneous transcatheter implantation of an aortic 
valve prosthesis for calcific aortic stenosis: first human case 
description. Circulation. 2002;106(24):3006-8.
14. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, 
Wenaweser P, et al. Percutaneous aortic valve replacement for 
severe aortic stenosis in high-risk patients using the second-and 
current third-generation self-expanding Corevalve prosthesis: 
device success and 30-day clinical outcome. J Am Coll Car-
diol. 2007;50(1):69-76.
15. Sarmento-Leite R, Quadros AS, Prates PRL, Zanatta LG, 
Salgado Filho PA, Grando T, et al. Implante valvular aórtico 
percutâneo: experiência inicial do sul do Brasil. Rev Bras 
Cardiol Invasiva. 2008;16(4):398-405.
16. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, 
Svensson LG, et al. Transcatheter versus surgical aortic-valve 
replacement in high-risk patients. N Engl J Med. 2011;364(23): 
2187-98.
17. Leon MB, Piazza N, Nikolsky E, Blackstone EH, Cutlip DE, 
Kappetein AP, et al. Standardized endpoint definitions for 
Transcatheter Aortic Valve Implantation clinical trials: a con-
sensus report from the Valve Academic Research Consortium. 
J Am Coll Cardiol. 2011;57(3):253-69.
18. Piazza N, de Jaegere P, Schultz C, Becker AE, Serruys PW, 
Anderson RH. Anatomy of the aortic valvar complex and its 
implications for transcatheter implantation of the aortic valve. 
Circ Cardiovasc Interv. 2008;1(1):74-81.
19. Webb JG, Chandavimol M, Thompson CR, Ricci DR, Carere RG, 
Munt BI, et al. Percutaneous aortic valve implantation ret-
rograde from the femoral artery. Circulation. 2006;113(6): 
842-50.
20. Gilard M, Eltchaninoff H, Iung B, Donzeau-Gouge P, 
Chevreul K, Fajadet J, et al. Registry of transcatheter aortic-
valve implantation in high-risk patients. N Engl J Med. 2012; 
366(18):1705-15.
21. Lemos PA, Saia F, Marzocchi A, Mariani Jr J, Esteves Filho A, 
Kajita LJ, et al. Implante transcateter de prótese valvular aór-
tica: perfil clínico e evolução de uma série consecutiva de 
75 casos do registro conjunto Universidade de Bolonha/ 
Hospital Sírio-Libanês. Rev Bras Cardiol Invasiva. 2011; 
19(1):24-7.
22. Gurvitch R, Toggweiler S, Willson AB, Wijesinghe N, Cheung A, 
Wood DA, et al. Outcomes and complications of transcatheter 
aortic valve replacement using a balloon expandable valve 
according to the Valve Academic Research Consortium (VARC) 
guidelines. EuroIntervention. 2011;7(1):41-8.
23. Stähli BE, Bunzli R, Grunenfelder J, Buhler I, Felix C, Bettex D, 
et al. Transcatheter Aortic Valve Implantation (TAVI) outcome 
according to standardized endpoint definitions by the Valve 
Academic Research Consortium (VARC). J Invasive Cardiol. 
2011;23(8):307-12.
24. El-Khally Z, Thibault B, Staniloae C, Theroux P, Dubuc M, Roy D, 
et al. Prognostic significance of newly acquired bundle branch 
block after aortic valve replacement. Am J Cardiol. 2004; 
94(8):1008-11.
25. Kolh P, Lahaye L, Gerard P, Limet R. Aortic valve replace-
ment in the octogenarians: perioperative outcome and clinical 
follow-up. Eur J Cardiothorac Surg. 1999;16(1):68-73.
